Glucagen

Glucagen is a prescription injectable medication whose active ingredient is glucagon, a peptide hormone used to raise blood glucose levels. It is supplied as a sterile solution for intramuscular, intravenous, or subcutaneous administration. Marketed in the European Union, Glucagen belongs to the antihypoglycemic therapeutic class and is indicated for the rapid treatment of severe hypoglycemia when oral glucose is not feasible in emergency settings by healthcare professionals.

Glucagen is employed primarily for the urgent correction of low blood glucose in clinical and emergency contexts.

- Treatment of severe hypoglycemia in patients with diabetes when oral carbohydrate intake is impossible. - Emergency management of hypoglycemia in unconscious or unable-to-swallow individuals. - Use during insulin overdose or accidental hypoglycemic events. - Administration in pre‑hospital settings by emergency medical services. - Adjunct therapy for diagnostic testing of pancreatic function (glucagon stimulation test) where appropriate.

The safety profile of Glucagen includes both frequently observed and less common adverse reactions.

Common: - Nausea or vomiting. - Abdominal discomfort or pain. - Headache. - Flushing or warmth. - Injection‑site pain, redness, or swelling. - Transient hyperglycemia.

Serious: - Allergic reactions, including anaphylaxis or severe rash. - Marked hyperglycemia requiring medical intervention. - Cardiovascular effects such as tachycardia, hypertension, or arrhythmias. - Pancreatitis. - Severe hypotension (rare).

Before using Glucagen, healthcare providers should consider several precautionary measures to ensure safe administration.

- Verify the patient’s diagnosis of hypoglycemia and assess the need for injectable glucagon. - Use caution in patients with pheochromocytoma or insulinoma due to potential exaggerated response. - Avoid use in individuals with known hypersensitivity to glucagon or formulation components. - Monitor blood glucose after administration to prevent rebound hyperglycemia. - Adjust dose in pediatric patients according to weight and clinical guidelines. - Ensure proper storage conditions (refrigerated, protected from light).

Glucagen may interact with certain medications, influencing its effectiveness or safety.

Avoid: - Concurrent use of beta‑blockers, which may mask typical glucagon‑induced tachycardia. - Combination with other antihypoglycemic agents that could cause unpredictable glucose fluctuations. - Use with monoamine oxidase inhibitors (MAOIs) due to potential hypertensive response.

Use with caution: - Concomitant administration of insulin or sulfonylureas; monitor glucose closely. - Co‑administration with catecholamines (e.g., epinephrine) may augment cardiovascular effects. - Use with diuretics that affect electrolyte balance; observe for signs of fluid shifts.